Dr. Jedd Wolchok, chief of Memorial Sloan Kettering’s Immunotherapuetics, told the Daily News that the “team science” collaborative model is the way forward in cancer research. In defence, Parker says a central principle behind the institute will be “freedom of innovation in concert with collaboration”.
Advertisement
The billionaire tech pioneer, who also served as the first president of Facebook, will spread the massive sum between six cancer centres in the United States. “The goal here is to rapidly move our discoveries to patients”.
“Any breakthrough made at one center is immediately available to another center without any kind of IP (intellectual property) entanglements or bureaucracy”, noted Parker in an interview with Reuters.
With a collaborative approach in mind, the Parker Institute was started back in July of 2015, hoping to create a sandbox effect among the top institutions; institutions such as: Memorial Sloan Kettering Cancer Center; Stanford Medicine; University of California, Los Angeles; University of California, San Francisco; University of Pennsylvania; and The University of Texas MD Anderson Cancer Center.
One example is the breakthrough melanoma drug Yervoy.
The event is to “unveil and celebrate a new philanthropic venture and recognize the heroes who, over the last decades, have brought us to this turning point in the war on cancer”, a statement from the foundation said. As TechCrunch notes, a significant amount of money has been invested by Parker on research into diabetes and allergies, as well as another $600m charitable foundation he set up past year.
Lanier said he’s already been able to boost research staff and fund projects with the new funds. Barring a hold, the study may begin with Institutional Review Board approval. The Parker Institute will encourage scientists to borrow from each other’s labs. This will help ensure that the immunotherapy works in every single person. Everything is exhaustively debated. Though the research will be conducted by researchers in their home institutions, they will get additional funding and access to other resources, including specialized data scientists and genetic engineering equipment.
“I want to make it a front-line treatment”, Parker said at the time.
Its focus will on the emerging field of cancer immunotherapy, which is now being led by Bristol-Myers Squibb’s ($BMY) Opdivo and Merck’s ($MRK) Keytruda, with a new PD-L1 drug from Roche ($RHHBY) expected to be approved by the FDA later this year. After months of treatment, Carter announced that doctors could no longer detect signs of cancer in his system. This new program, called the Parker Institute for Cancer Immunotherapy, will focus on immunotherapy, an experimental cancer treatment that shows promise toward developing a potential cure.
Advertisement
“I think it’s wonderful”, Sharma said. They mutate, change and learn how to escape the drugs we use to try to treat them. “They protect cells from part of the immune system”.
